Cimetidine suppression of nocturnal gastric secretion in active duodenal ulcer.
Nocturnal pain and gastric hypersecretion are common in duodenal ulcer. Therefore, we investigated the antisecretory effects of a new H2-receptor antagonist, cimetidine, in 200-, 300- or 400-mg doses, taken orally at bedtime. The 200-mg dose did not cause a statistically significant change in nocturnal (midnight to 7 a.m.) acid output and had only a borderline effect on pH. However, the 300-mg and 400-mg doses significantly (P less than 0.001) lowered acid output and increased (P less than 0.01) intragastric pH. All doses caused substantial decreases in secretory volume output. After a 400-mg dose, half the patients remained anacidic for eight hours. Dose-related increases of drug blood levels were observed and correlated with the degree and duration of inhibition of acid output. Serum gastrin levels were unaffected. Cimetidine appears to be a potent inhibitor of nocturnal gastric secretion.
D000284:Administration, Oral; D000328:Adult; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004381:Duodenal Ulcer / Q000503:physiopathology*; D005745:Gastric Acidity Determination; D005750:Gastric Juice / Q000378:metabolism*; D006146:Guanidines / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012636:Secretory Rate / Q000187:drug effects; D013997:Time Factors
D006146:Guanidines; D006634:Histamine H1 Antagonists; D007093:Imidazoles; D010919:Placebos